HB-0046

N/A

Report date: 2025/03/03 10:41:09

Base Information

Drug NameHB-0046
Drug Alias NameHB0046HB-0046
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionEctonucleoside triphosphate diphosphohydrolase 1 inhibitors5'-nucleotidase inhibitors
TargetsEctonucleoside triphosphate diphosphohydrolase 15'-nucleotidase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Huaota Biopharmaceutical Co LtdHuaBo Biopharm Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuaBo Biopharm Co LtdShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A